Description
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)
Contact Email: clinicalresearch@sutterhealth.org
Location: CPMC (San Francisco)
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
March 07, 2019